Pfizer Cuts Recifercept for Achondroplasia Program
Pfizer punts pair of orphan drugs amid rare disease R&D rethink Pfizer, amid a rethink of its rare disease R&D strategy, has punted (PDF) a pair of orphan drug candidates from its…
Pfizer
-
-
Achondroplasia · Ascendis Pharma · BioMarin · Hypochondroplasia · Limb Lengthening · Pfizer · QED Therapeutics · Skeletal Dysplasia
The Perfect Date: National DNA Day
The perfect date: April 25th…because it’s not too hot, not too cold. All you need is a light jacket…Oh! And it’s also #NationalDNADay! National DNA Day is a global movement…
-
Key Measurement Concepts and Appropriate Clinical Outcome Assessments in Pediatric Achondroplasia Clinical Trials
Author(s): Natalie Aldhouse, MSc (Presenting Author); Helen Kitchen, MSc (Co-Author); Chloe Johnson, MSc (Co-Author); Chris Marshall, MSc (Co-Author); Hannah Pegram, BSc (Co-Author); Sheryl Pease, MBA PMP (Co-Author); Sam Collins, MD (Co-Author);…
-
Prospects for Pharmaceutical Treatment of Achondroplasia
John B. Cannon, Ph.D Achondroplasia is a form of dwarfism that occurs about once in every 20,000 births. It arises from a defect in the process of bone growth in…
-
Pfizer Acquires Clinical-Stage Biotech Therachon
Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form of short-limb dwarfism NEW YORK & BASEL, Switzerland–Pfizer (NYSE: PFE) today…
-
Therachon Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia
BASEL, Switzerland, February 14, 2018 – Therachon AG, a biotechnology company focused on rare genetic diseases, today announced the dosing of the first subject in its Phase 1 trial for TA-46,…
